Bank of America Corp DE Has $95.70 Million Position in West Pharmaceutical Services, Inc. $WST

Bank of America Corp DE cut its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 28.2% during the 1st quarter, HoldingsChannel reports. The firm owned 381,813 shares of the medical instruments supplier’s stock after selling 150,033 shares during the period. Bank of America Corp DE’s holdings in West Pharmaceutical Services were worth $95,698,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Elyxium Wealth LLC bought a new position in West Pharmaceutical Services in the 4th quarter valued at approximately $25,000. CYBER HORNET ETFs LLC bought a new stake in shares of West Pharmaceutical Services during the second quarter worth $25,000. Cornerstone Planning Group LLC grew its stake in shares of West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 50 shares during the last quarter. Bayban acquired a new position in shares of West Pharmaceutical Services during the fourth quarter worth $27,000. Finally, Private Trust Co. NA lifted its stake in shares of West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 61 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $353.61 on Friday. The firm has a market cap of $24.89 billion, a PE ratio of 45.28, a price-to-earnings-growth ratio of 2.47 and a beta of 1.15. The firm’s fifty day moving average is $342.97 and its 200-day moving average is $292.25. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. West Pharmaceutical Services, Inc. has a 52 week low of $223.83 and a 52 week high of $386.00.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. The business had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.West Pharmaceutical Services’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Sell-side analysts predict that West Pharmaceutical Services, Inc. will post 8.94 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is 11.27%.

Analysts Set New Price Targets

WST has been the topic of several recent research reports. Citigroup raised their price objective on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Stephens reiterated an “overweight” rating and issued a $360.00 target price on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Barclays raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Finally, Wolfe Research initiated coverage on West Pharmaceutical Services in a report on Monday, June 1st. They set an “outperform” rating and a $375.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $368.08.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.